Quick Answer
Eloxx Pharmaceuticals, Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025.
Eloxx Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.49 | +41.7% |
| 2024 | -$0.84 | +87.3% |
| 2023 | -$6.63 | +60.2% |
| 2022 | -$16.65 | +56.4% |
| 2021 | -$38.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | -$1.31 | +62.2% | +33.2% |
| June 30, 2023 | -$1.96 | +60.0% | +31.9% |
| March 31, 2023 | -$2.88 | +46.3% | +17.0% |
| September 30, 2022 | -$3.47 | -3054.5% | +29.2% |
| June 30, 2022 | -$4.90 | -807.4% | +8.6% |
| March 31, 2022 | -$5.36 | — | -4772.7% |
| September 30, 2021 | -$0.11 | — | +79.6% |
| June 30, 2021 | -$0.54 | — | — |
- Eloxx Pharmaceuticals, Inc. showed an increase of +41.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Eloxx Pharmaceuticals, Inc.’s diluted eps has grown by 98.7% (from $38.15 per share (loss) to $0.49 per share (loss)).
- The most recent figure is from Eloxx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: